144036-71-5

Usage

Uses

Used in Pharmaceutical Industry:
Acetic acid, (1-methylhydrazino)-, 1,1-dimethylethyl ester (9CI) is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a versatile building block for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, Acetic acid, (1-methylhydrazino)-, 1,1-dimethylethyl ester (9CI) is utilized as a precursor in the production of various agrochemicals, such as pesticides and herbicides. Its reactivity and compatibility with other chemical compounds make it a valuable component in the formulation of effective and targeted agricultural products.
It is important to handle and store Acetic acid, (1-methylhydrazino)-, 1,1-dimethylethyl ester (9CI) with care to prevent any potential hazards due to its moderate toxicity and irritating properties. Proper safety measures, such as wearing protective gear and ensuring proper ventilation, should be taken during its use in both pharmaceutical and agrochemical applications.

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 60-34-4 methylhydrazine 
• 107-59-5 tert-Butyl chloroacetate 
• 5616-81-9 sarcosine tert-butyl ester 

Downstream Products

• 144036-61-3 [N'-((3R,5R)-5-Benzyloxymethoxy-3,6-bis-tert-butoxycarbonylamino-hexanoyl)-N-methyl-hydrazino]-acetic acid tert-butyl ester 
• 551964-58-0 t-Butyl {N'-[(3R/S)-t-butoxycarbonylamino-3-(4-t-butoxycarbonylaminophenyl)propionyl]-N-methylhydrazino}acetate 
• 551964-62-6 {N'-[3-tert-butoxycarbonylamino-3-(3-tert-butoxycarbonylamino-phenyl)-propionyl]-N-methyl-hydrazino}-acetic acid tert-butyl ester 
• 540721-35-5 [N'-(6-benzyloxycarbonylamino-3-tert-butoxycarbonylamino-hexanoyl)-N-methyl-hydrazino]-acetic acid tert-butyl ester 
• 551964-21-7 (N'-{3-tert-butoxycarbonylamino-5-(tert-butyl-dimethyl-silanyloxy)-6-[methyl-(2-nitro-benzenesulfonyl)-amino]-hexanoyl}-N-methyl-hydrazino)-acetic acid tert-butyl ester 
• 551964-20-6 {N'-[3-tert-butoxycarbonylamino-5-(tert-butyl-dimethyl-silanyloxy)-6-(2-nitro-benzenesulfonylamino)-hexanoyl]-N-methyl-hydrazino}-acetic acid tert-butyl ester 
• 551964-24-0 (N'-{3-tert-butoxycarbonylamino-5-(tert-butyl-dimethyl-silanyloxy)-6-[ethyl-(2-nitro-benzenesulfonyl)-amino]-hexanoyl}-N-methyl-hydrazino)-acetic acid tert-butyl ester 
• 551964-26-2 (N'-{3-tert-butoxycarbonylamino-5-(tert-butyl-dimethyl-silanyloxy)-6-[(2-nitro-benzenesulfonyl)-propyl-amino]-hexanoyl}-N-methyl-hydrazino)-acetic acid tert-butyl ester 
• 1012367-54-2 tert-butyl (S,E)-2-(2-(6-(benzyloxycarbonylamino)-3-(tert-butoxycarbonylamino)hex-4-enoyl)-1-methylhydrazinyl)acetate 
• 1037825-20-9 t-butyl 2-(1-methylhydrazinyl)acetate p-toluenesulfonic acid salt 

Relevant academic research and scientific papers

Synthesis and nucleic acid binding studies of novel pyrrolidinyl PNA carrying an N-amino-N-methylglycine spacer

Two novel pyrrolidinyl peptide nucleic acids comprising alternating sequences of thymine-modified D- or L-proline and an N-amino-N-methylglycine spacer were synthesized using solid-phase methodology. UV and CD titrations together with a gel-binding shift assay revealed that neither of the homothymine PNA decamers bind to their complementary DNA or RNA. This was considered to be due to an unfavorable secondary structure which could not be alleviated by the presence of the positively charged protonated amine in the PNA backbone.

Efficient total synthesis of (+)-negamycin, a potential chemotherapeutic agent for genetic diseases

Herein, we describe an efficient strategy for the total synthesis of (+)-negamycin using commercially available achiral N-Boc-2-aminoacetaldehyde as starting material with 42% overall yield for a limited number of steps. The Royal Society of Chemistry.

N- and C-terminal modifications of negamycin

Negamycin 1 is a bactericidal antibiotic with activity against Gram-negative bacteria, and served as a template in an antibiotic discovery program. An orthogonally protected β-amino acid derivative 3a was synthesized and used in parallel synthesis of negamycin derivatives on solid support. This advanced intermediate was also used for N- and C-terminal modifications using solution-phase methodologies. The N-terminal modifications have resulted in the identification of active analogues, whereas the C-terminal modifications resulted in complete loss of antibacterial activity. The N-methyl negamycin analogue, 19a, inhibits protein synthesis (IC50=2.3 μM), has antibacterial activity (Escherichia coli, MIC=16 μg/mL), and is efficacious in an E. coli murine septicemia model (ED50=16.3 mg/kg).

Beta-amino acid derivatives useful for the treatment of bacterial infections

The invention provides compounds that are useful for the treatment of bacterial infections in mammals. More specifically, it is directed to beta-amino acid derivatives or pharmaceutically acceptable salts, prodrugs, or isomers of those compounds that are